BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11844676)

  • 1. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.
    Sawa M; Kondo H; Nishimura S
    Bioorg Med Chem Lett; 2002 Feb; 12(4):581-4. PubMed ID: 11844676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
    Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
    Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
    J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
    Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
    Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.
    Zhang X; Gonnella NC; Koehn J; Pathak N; Ganu V; Melton R; Parker D; Hu SI; Nam KY
    J Mol Biol; 2000 Aug; 301(2):513-24. PubMed ID: 10926524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
    Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
    Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
    Lovejoy B; Welch AR; Carr S; Luong C; Broka C; Hendricks RT; Campbell JA; Walker KA; Martin R; Van Wart H; Browner MF
    Nat Struct Biol; 1999 Mar; 6(3):217-21. PubMed ID: 10074939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of human neutrophil collagenase reveals large S1' specificity pocket.
    Stams T; Spurlino JC; Smith DL; Wahl RC; Ho TF; Qoronfleh MW; Banks TM; Rubin B
    Nat Struct Biol; 1994 Feb; 1(2):119-23. PubMed ID: 7656015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
    Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
    J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of ferulic Acid amides as selective matrix metalloproteinase inhibitors.
    Shi ZH; Li NG; Shi QP; Tang H; Tang YP; Li W; Yin L; Yang JP; Duan JA
    Med Chem; 2013 Nov; 9(7):947-54. PubMed ID: 23061601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
    Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
    Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity.
    Finzel BC; Baldwin ET; Bryant GL; Hess GF; Wilks JW; Trepod CM; Mott JE; Marshall VP; Petzold GL; Poorman RA; O'Sullivan TJ; Schostarez HJ; Mitchell MA
    Protein Sci; 1998 Oct; 7(10):2118-26. PubMed ID: 9792098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases.
    Aureli L; Gioia M; Cerbara I; Monaco S; Fasciglione GF; Marini S; Ascenzi P; Topai A; Coletta M
    Curr Med Chem; 2008; 15(22):2192-222. PubMed ID: 18781944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF
    Erdeljac N; Thiehoff C; Jumde RP; Daniliuc CG; Höppner S; Faust A; Hirsch AKH; Gilmour R
    J Med Chem; 2020 Jun; 63(11):6225-6237. PubMed ID: 32379447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
    Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
    Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.
    Reiter LA; Rizzi JP; Pandit J; Lasut MJ; McGahee SM; Parikh VD; Blake JF; Danley DE; Laird ER; Lopez-Anaya A; Lopresti-Morrow LL; Mansour MN; Martinelli GJ; Mitchell PG; Owens BS; Pauly TA; Reeves LM; Schulte GK; Yocum SA
    Bioorg Med Chem Lett; 1999 Jan; 9(2):127-32. PubMed ID: 10021913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis-substituted malonic acid hydroxamate derivatives as inhibitors of human neutrophil collagenase (MMP8).
    Graf von Roedern E; Brandstetter H; Engh RA; Bode W; Grams F; Moroder L
    J Med Chem; 1998 Jul; 41(16):3041-7. PubMed ID: 9685244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.
    Kohno T; Hochigai H; Yamashita E; Tsukihara T; Kanaoka M
    Biochem Biophys Res Commun; 2006 May; 344(1):315-22. PubMed ID: 16603129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.